Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

Blood blood.2024026216.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott, William Wesson, Pilar Thangwaritorn, Raeef L Rahman, Forat Lutfi, Marc Hoffmann, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 389.

https://doi.org/10.1182/blood-2024-205983

Published: 2024

Journal Articles

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Jordan Snyder, Dennis Grauer, Nausheen Ahmed, Al-Ola Abdallah, Marc Hoffmann, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 935.

https://doi.org/10.1182/blood-2024-199893

Published: 2024

Journal Articles

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry Skikne, Tara L. Lin, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Omar Alkharabsheh, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2024-205757

Published: 2024

Journal Articles

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Sara Leidy, Jordan Snyder, James A Davis, William Wesson, Brian Hess, Ryan Jacobs, Madalyn Edmonds, Nausheen Ahmed, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2024-199658

Published: 2024

Journal Articles

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Ishita Kamboj, Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, James A Davis, Aliya Rashid, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Abdullah Mohammad Khan, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 2411.2.

https://doi.org/10.1182/blood-2024-199187

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Journal Articles

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Blood (2024) 144 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2024-210263

Published: 2024

Journal Articles

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 526.

https://doi.org/10.1182/blood-2024-199139

Published: 2024

Journal Articles

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Alaa Ali, Nausheen Ahmed, Soyoung Kim, Matthew Bye, Sayeef Mirza, Alex Gordon Sieg, Christopher Strouse, Kalyan Nadiminti, Priyanka A. Pophali, Rammurti T. Kamble, Lohith Gowda, Cameron J. Turtle, Christine L. Phillips, Marcelo C. Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop

Blood (2024) 144 (Supplement 1): 71.

https://doi.org/10.1182/blood-2024-200269

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, Darryl Chang, Barry Paul, Hira Shaikh, Christopher Strouse, Emily Struble, Andrew Vegel, James A Davis, Kimberly M Green, Hamza Hashmi, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Reed Friend

Blood (2024) 144 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2024-208799

Published: 2024

Journal Articles

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2411.7.

https://doi.org/10.1182/blood-2024-204158

Published: 2024

Journal Articles

Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study

Razan Mansour, Kimberly M Green, Mark Chang, Gray Magee, James A Davis, Shebli Atrash, Nausheen Ahmed, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Zahra Mahmoudjafari, Al-Ola Abdallah, Barry Paul, Nicole Twardowski, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 1965.

https://doi.org/10.1182/blood-2024-209196

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Journal Articles

Efficacy of Ruxolitinib with Corticosteroids in Idiopathic Pneumonia Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience and Systematic Review

Moazzam Shahzad, Muhammad Atif Khan, Muhammad Kashif Amin, Zouina Sarfraz, Fizza Zulfiqar, Hana Qasim, Sibgha Gull Chaudhary, Iqra Anwar, Faiza Humayun Khan, Rajat Bansal, Kyle Brownback, Nausheen Ahmed, Sunil Abhyankar, Joseph P. McGuirk, Anurag Singh, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7380.

https://doi.org/10.1182/blood-2024-200435

Published: 2024

Journal Articles

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Joseph G Bennett, Kamen Kossow, Leah Diebolt, Nicole Twardowski, Jianzheng Wu, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Brian Hess, James A Davis, Al-Ola Abdallah, Nausheen Ahmed, Joseph P. McGuirk, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 6556.

https://doi.org/10.1182/blood-2024-201728

Published: 2024

Journal Articles

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Blood (2024) 144 (Supplement 1): 7242.

https://doi.org/10.1182/blood-2024-206536

Published: 2024

Journal Articles

Outcomes in Underweight Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Moazzam Shahzad, Aleenah Mohsin, Muhammad Atif Khan, Aqeeb Ur Rehman, Sohaib Irfan, Muhammad Kashif Amin, Matthew McGuirk, Sibgha Gull Chaudhary, Faiza Humayun Khan, Iqra Anwar, Nausheen Ahmed, Al-Ola Abdallah, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7377.

https://doi.org/10.1182/blood-2024-199383

Published: 2024

Journal Articles

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation

Sibgha Gull Chaudhary, Moazzam Shahzad, Iqra Anwar, Muhammad Kashif Amin, Sohaib Irfan, Matthew McGuirk, Shaun DeJarnette, Nausheen Ahmed, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7305.

https://doi.org/10.1182/blood-2024-198392

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Efficacy of Ruxolitinib with Corticosteroids in Idiopathic Pneumonia Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience and Systematic Review

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Outcomes in Underweight Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only